Select Vaccines chief banned from corporate world for 10 years; GSK, AZ could face tough year;

 @FierceBiotech: Biotechs tackle new frontiers in vaccine production. Report | Follow @FierceBiotech 

 @JohnCFierce: It looks like just about every biotech out there wants a piece of the new $1B federal tax credit/grant. Report | Follow @JohnCFierce

> Dr. Martin Soust, a former chief executive of Select Vaccines, will pay an $80,000 penalty and be banned from the corporate world for 10 years for buying shares in his listed biotech company to push the share price higher. Report

> Britain's leading drugmakers, GlaxoSmithKline and AstraZeneca, should report healthy quarterly results next week, helped by swine flu and other one-offs--but the rest of the year will be more tricky. News

> A new vaccine against Alzheimer's, developed by the Austrian biotechnology firm Affiris, will soon be tested in six European countries, the company announced Friday. Story

> The City of Chandler has signed an 11-year lease for 38,146 square feet at San Tan Tech Center for a biotechnology incubator site. Story

> Cellsafe International Group, a regional stem cell biotechnology company, is to expand its biotechnology business and research and development activities in Indonesia following a strategic partnership with PT Kimia Farma TBK (Kimia Farma). Item

> Urigen Pharmaceuticals, a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it has filed a request for an FDA meeting to advance the URG101 clinical program and mutually agreed with Oceana Therapeutics to terminate their Consulting Agreement effective immediately. Release

> Oncolytics Biotech announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham. Release

And Finally... Hoping the county will become a biotech hub, the Los Angeles County board of supervisors approved a pilot project to offer free laboratory space in an unused hospital for a biotech incubator. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.